Nasal Insulin IND
Executive Summary
California Biotechnology Inc. receives FDA approval for Phase I clinical testing on Nazlin, nasally administered insulin. The insulin product is the first to reach the IND stage for Cal Bio. Lilly has a letter of intent to develop and market the nasal formulation. Cal Bio Chairman William Baker commented that Cal Bio expects "to conclude commercial arrangements with Lilly on licensing of our Nazdel technology with insulin" following completion of Phase I work.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.